COVID-19 Presentation in Association with Myasthenia Gravis: A Case Report and Review of the Literature

COVID-19 Presentation in Association with Myasthenia Gravis: A Case Report and Review of the Literature

Currently, there are scarce data on how COVID-19 affects people with myasthenia gravis. Theoretically, there is a higher risk of experiencing severe manifestations of COVID-19 due to the common use of immunosuppressive drugs and potential respiratory failure in relation to respiratory muscle weaknes...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Case reports in infectious diseases 2020-01, Vol.2020 (2020), p.1-4
Hauptverfasser: Aksoy, Elif, Oztutgan, Turgut
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies
Case Report
Case reports
Coronaviruses
COVID-19
Cytokines
Dysphagia
Health aspects
Immunosuppressive agents
Infections
Intensive care
Intubation
Lung diseases
Medical prognosis
Mortality
Myasthenia gravis
Neuromuscular diseases
Oxygen saturation
Oxygen therapy
Pandemics
Patients
Plasma
Pneumonia
Respiratory failure
Severe acute respiratory syndrome
Severe acute respiratory syndrome coronavirus 2
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Currently, there are scarce data on how COVID-19 affects people with myasthenia gravis. Theoretically, there is a higher risk of experiencing severe manifestations of COVID-19 due to the common use of immunosuppressive drugs and potential respiratory failure in relation to respiratory muscle weakness. This is one of the early cases of COVID-19 reported in association with myasthenia gravis. Here, we highlight the prognosis, discuss the pathophysiological mechanisms, and prompt the consideration of convalescent plasma therapy in myasthenia gravis patients with concomitant COVID-19.
ISSN:2090-6625
2090-6633
DOI:10.1155/2020/8845844